

Client: TransCure bioServices
 Intended publication: Press Release
 US/UK spelling: US
 Word count: 315 [main body]

TransCure bioServices offers BioVolume 3D imaging for insightful preclinical oncology research

The Humanized Mouse Preclinical CRO provides a new service to study tumor progression in never-before-seen depth.




Image caption: BioVolume accurately and reproducibly measures tumor volume.

<Archamps, 2023> — TransCure bioServices adds BioVolume 3D imaging to its service offerings, enabling them to deliver even higher quality tumor growth results to customers. With a deeper understanding of how tumors grow and respond to stimuli, researchers can more quickly develop the highly efficacious treatments urgently needed to tackle different cancers. The new service is a

world first in 3D imaging, allowing the measurement and visualization of tumor growth in animal models across preclinical research, oncology, and drug development.

Mouse models with subcutaneous tumor xenografts are the most prevalent model used across the globe, enabling researchers to study early tumor progression and treatment response *in vivo*. The tumor volume provides the most useful data in monitoring these aspects, but traditional measurements can be prone to user error and are invasive, causing discomfort to the mouse.

BioVolume reconstructs tumors from 3D, RGB, and thermal imaging. The solution is non-invasive, using a machine learning algorithm to automatically calculate subcutaneous tumor length, height, and width. The approach also has low user variability, thereby increasing measurement accuracy and enhancing experiment reproducibility. Inclusion of this technology bolsters TransCure bioServices' extensive technical service offerings for greater success in preclinical oncology research, while also enabling them to uphold their Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) commitment to improved animal welfare.

"BioVolume technology is a significant leap forward for tumor measurements," says **Dr Sébastien Tabruyn, General Manager and Chief Scientific Officer (CSO), TransCure bioServices**. "It allows TransCure bioServices to better support our customers with much deeper insight into tumor progression by improving measurement accuracy and inter-operator consistency, driving more reliable results. By combining BioVolume with our existing breadth of high-quality services like flow cytometry and *in vitro* assays, we can offer scientists the comprehensive data package they need for their preclinical studies to deliver better oncology treatments."

For further information on TransCure bioServices' new offering, please visit <https://transcurebioservices.com/news/transcure-bioservices-improves-its-services-with-3d-tumor-imaging-from-biovolume/>

About TransCure bioServices:

[TransCure bioServices](#) is a unique fee-for-service Contract Research Organization (CRO) with expertise in conducting research using [humanized mouse models](#), supported by cutting edge technologies. The company offers qualified services across a range of disease models, from preliminary discussion through tailor-made protocols, experiments, and reporting. TransCure bioServices adheres to rigorous standards including [AAALAC](#) accreditation and the three R's: Replacement, Reduction, and Refinement of responsible animal use.

For further information:

Kiave Ho Wang Yin, PhD

Director of Innovation and Business Development

TransCure bioServices

kiave.howangyin@tcbioservices.com